Scarica l'app Stockscreener
17.91
0.83%
-0.15
Dopo l'orario di chiusura:
17.92
0.01
+0.06%
Precedente Chiudi:
$18.06
Aprire:
$18
Volume 24 ore:
2.31M
Relative Volume:
0.81
Capitalizzazione di mercato:
$56.58B
Reddito:
$29.85B
Utile/perdita netta:
$776.90M
Rapporto P/E:
74.38
EPS:
0.2408
Flusso di cassa netto:
$4.35B
1 W Prestazione:
+0.45%
1M Prestazione:
-4.48%
6M Prestazione:
+21.51%
1 anno Prestazione:
+18.30%
Intervallo 1D:
$17.87
$18.19
Intervallo di 1 settimana:
$17.78
$18.39
Portata 52W:
$12.99
$18.82
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
17.91 | 57.06B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
113.35 | 49.23B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.80 | 43.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.74 | 34.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
522.83 | 23.34B | 3.18B | 1.33B | 1.04B | 27.90 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Ripresa | Morgan Stanley | Overweight |
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
What's Going On With Eli Lilly On Monday? - Benzinga
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical ADR sees IBD RS rating climb to 76 - MSN
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Finviz
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Stocks To Watch: Takeda Pharmaceutical ADR Sees Relative Strength Rating Rise To 83 - Investor's Business Daily
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
Apple, Visa, KLA-Tencor and more set to report earnings Thursday By Investing.com - Investing.com Nigeria
Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
US earnings seasonQ4 2025 - Interactive Investor
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Takeda Pharmaceutical ADR Sees IBD RS Rating Climb To 76 - Investor's Business Daily
Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – GETTEX:TKDA - TradingView — Track All Markets
The Truth About Takeda Pharmaceutical Co Ltd: Is This Pharma Giant a Hidden Power Play for Your Port - AD HOC NEWS
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
Ethic Inc. Buys 43,295 Shares of Takeda Pharmaceutical Co. $TAK - Defense World
Takeda Pharmaceutical (NYSE:TAK) Strengthens Position in Healthcare - Kalkine Media
Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.81%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):